Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

  • In development
  • GID-TA10326
  • Expected publication date: TBC

Status:
In progress
Decision:
Selected
Process:
TA

Timeline

Key events during the development of the guidance:

Date Update
21 March 2017 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual